Our research project at a glance
Cancer cells have deregulated signaling pathways that are involved in cell proliferation, survival, and tumor progression. Our general aim is to understand the molecular pathway abnormalities in cancer cells and translate our findings to the development of new therapeutic strategies in the clinic, in particular in lung cancers and melanoma.
Our general aim is to understand molecular pathway abnormalities in cancer cells and to translate these laboratory results into the development of new therapeutic strategies.
We focus first on the receptor tyrosine kinase (RTK)/RAS/MAPK and RHOGTPase pathways to understand their connections with the control of cell proliferation, survival and tumor progression, and to design new therapeutic strategies.
Second, we study the signaling and repair mechanisms of DNA double-strand breaks (DSB) produced in transcribed regions, their cross-talk with oncogenic signaling, to understand their role in oncogenesis and resistance to targeted therapies.
Team strengths in the leading-edge biotechnologies of GFP-based protein/protein interaction and nanobody-based biosensors contribute to the discovery of new biological and clinical findings. Expertise in signal transduction and DNA damage response pathway has contributed directly and indirectly to new concepts in the resistance to targeted therapies and new target discovery.
In close collaboration with clinical departments, we develop translational and clinical research in lung cancers and melanomas.
- Oncogenic signaling
- RTK/RAS/MAPK and RHOGTPase pathways
- Cell stress and double-strand break signaling
- Split GFP
- Lung cancers
- Translational research
- Clinical trials
Labels and networks
Grants and funders
- Fondation pour la Recherche Médicale
- Ligue Nationale Contre le Cancer
- Agence Nationale de la Recherche
- Fondation de France
- Fondation Roland Garrigou
- Centre Hospitalier Universitaire de Toulouse
- Université Fédérale de Toulouse Midi-Pyrénées
- Région Occitanie Pyrénées – Méditerranée
- Cancéropôle Grand Sud-Ouest
- CISBIO Bioassays
EMBO Mol Med, 9 (2), pp. 238-250, 2017, ISSN: 1757-4684 (Electronic) 1757-4676 (Linking).
Oncogene, 35 (14), pp. 1760-9, 2016, ISSN: 1476-5594 (Electronic) 0950-9232 (Linking).
Nucleic Acids Res, 44 (3), pp. 1161-78, 2016, ISSN: 1362-4962 (Electronic) 0305-1048 (Linking).
J Thorac Oncol, 11 (9), pp. e109-12, 2016, ISSN: 1556-1380 (Electronic) 1556-0864 (Linking).
Elife, 5 , 2016, ISSN: 2050-084X (Electronic) 2050-084X (Linking).
Lancet Oncol, 17 (5), pp. 642-50, 2016, ISSN: 1474-5488 (Electronic) 1470-2045 (Linking).
Oncotarget, 6 (17), pp. 15250-64, 2015, ISSN: 1949-2553 (Electronic) 1949-2553 (Linking).
Mol Cell Biol, 34 (16), pp. 3144-55, 2014, ISSN: 1098-5549 (Electronic) 0270-7306 (Linking).
Sci Rep, 3 , pp. 2854, 2013, ISSN: 2045-2322 (Electronic) 2045-2322 (Linking).
J Clin Oncol, 31 (16), pp. 1997-2003, 2013, ISSN: 1527-7755 (Electronic) 0732-183X (Linking).